Monthly Archives: November 2023

Novo Nordisk’s NVO, +1.16% popular weight-loss drug Wegovy significantly cut the risk of heart attack, stroke or death due to cardiovascular disease in people who do not have diabetes, according to new data from a large international clinical trial.  Patients taking semaglutide, the active ingredient in Wegovy and Ozempic, for more than three years had […]

Companies Novo Nordisk A/S Follow Eli Lilly and Co Follow PHILADELPHIA, Nov 11 (Reuters) – Novo Nordisk (NOVOb.CO) on Saturday said the heart protective benefits of its wildly popular Wegovy obesity treatment are due to more than weight loss alone, according to new data presented at a major medical meeting on Saturday. Early data from […]

The prescription weight loss drug semaglutide, known by the brand names Ozempic and Wegovy, can help prevent cardiovascular disease in overweight adults, according to a recent international trial that included the Cleveland Clinic. One in five of the trial’s participants, who were overweight adults with no history of diabetes, saw improvements in several risk factors […]

Semaglutide, the active ingredient in Ozempic and Wegovy, reduced the risk of serious cardiovascular events by 20% in overweight and obese people with established cardiovascular disease, according to results from a large randomized presented today at the American Heart Association Scientific Sessions meeting in Philadelphia. Semaglutide had been previously shown to reduce cardiovascular events by […]

The results of a large clinical trial suggest the obesity medication could also change the landscape of cardiovascular care. A pivotal new study suggests that the weight loss drug Wegovy cut the risk of heart attack, stroke or death from cardiovascular issues by 20 percent among overweight or obese people with heart disease — a […]

PHILADELPHIA — Novo Nordisk’s obesity drug Wegovy notably cut the risk of heart attacks in a landmark cardiovascular trial that affirms the treatment offers health benefits beyond weight loss. The company in August had announced that in this trial, called Select, Wegovy reduced the overall rate of major heart problems — heart attacks, stroke, or […]

CNN  —  Results from a landmark clinical trial this summer suggested, for the first time, that a medication given for weight loss alone could reduce the risk of heart attack, stroke or heart-related death in people with cardiovascular disease, bolstering physicians’ excitement about an already-exploding class of new medicines. Novo Nordisk’s Wegovy, part of the […]

Novo Nordisk’s Wegovy slashed the risk of serious cardiovascular complications in people with obesity and heart disease. Researchers presented the full results of Novo’s Select trial Saturday at the American Heart Association Scientific Sessions and simultaneously published in the New England Journal of Medicine. The findings could expand use of Wegovy and help Novo maintain […]

Not only can the injectable diabetes drugs help people lose weight, a new study finds they may also prevent future heart attacks. CLEVELAND — The American Heart Association is holding its Scientific Sessions meeting in Philadelphia today.  The first study is being presented by Cleveland Clinic cardiologist, Michael Lincoff, MD, and it’s big news, but […]

Findings from a multi-center, international clinical trial reported by a Cleveland Clinic physician show that semaglutide reduced cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease who don’t have diabetes.  Semaglutide is primarily prescribed for adults with type 2 diabetes but is also approved for chronic weight management in adults […]